Skip to content
value.today

Turn Therapeutics Inc.

Turn Therapeutics Inc. is listed today as Turn Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Turn Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$2 MPrivate placement after listingUnder $2 million

Turn Therapeutics Inc.: Private sale, Aug 2026

Investors in this round

8 investors had bought by the notice of Aug 26, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
$15,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley Burnam · Executive Officer, Director
  • Neilesh Shailesh Ghodadra · Executive Officer, Director
  • Zuraiz Chaudhary · Executive Officer
  • Andrew William Gengos · Director
  • Arthur F Golden · Director
  • Kent F Kester · Director
  • Martin William Dewhurst · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Zuraiz Chaudhary, VP Finance & Chief Accounting Officer. Source: SEC Form D, newest notice filed Aug 26, 2026. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Turn Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

That is all the official record says: Turn Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Turn Therapeutics Inc. are on record.

Investors#

No investor of Turn Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Turn Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Turn Therapeutics Inc.
NameRoleNamed in
Bradley BurnamExecutive officerAug 2026
Neilesh Shailesh GhodadraExecutive officerAug 2026
Zuraiz ChaudharyExecutive officerAug 2026
Andrew William GengosDirectorAug 2026
Arthur F GoldenDirectorAug 2026
Bradley BurnamDirectorAug 2026
Kent F KesterDirectorAug 2026
Martin William DewhurstDirectorAug 2026
Neilesh Shailesh GhodadraDirectorAug 2026

Went public since 2025. Its SEC number is that of a company listed on a stock exchange.